The 5-HT receptor field is currently expanding by leaps and bounds. This growth spurt was triggered by many factors, perhaps the most important being the development of drugs that interact selectively with the various receptor subtypes. The currently available drugs are far from ideal, and it is likely that, with the emerging interest of pharmaceutical firms in the possible clinical applications of directly acting 5-HT agonists and antagonists, even more specific and potent agents will become available. Basic studies evaluating the selectivity of newly developed drugs have largely depended on in vitro models, such as radioligand binding to membrane preparations; future studies should include an examination of specificity in vivo, since this may not reflect that found in vitro.
KeywordsReceptor Subtype Receptor Field Radioligand Binding Growth Spurt Pharmaceutical Firm
- Lubbert, H., Hoffman, B. J., Snutch, T. P., van Dyke, T., Levine, A. J., Hartig, P. R., Lester, H. A., and Davidson, N. (1987) cDNA cloning of a serotonin 5HT1C receptor by electrophysiological assays of mRNA-injected Xenopus oocytes. Proc. Natl Acad. Sci., USA. 84, 4332–4336.PubMedCrossRefGoogle Scholar